What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Gefurulimab demonstrated statistically significant improvements in MG-ADL and QMG scores compared to placebo in a phase 3 trial. However, the study did not compare gefurulimab directly with active competitors like ravulizumab or zilucoplan, limiting the ability to assess its relative effectiveness within the class.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-utility analysis, ICER, or economic model was identified for gefurulimab. Therefore, cost-effectiveness cannot be assessed.
Is there quality-of-life evidence payers weigh? — Quality of life
HRQoL improvements were observed in MG-QOL15r, Neuro-QoL Fatigue, and EQ-5D-5L measures, with statistically significant changes reported. However, these results were presented in congress abstracts and not fully peer-reviewed, limiting the robustness of the evidence.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Gefurulimab showed a similar overall safety profile to placebo, with no increase in serious adverse events. Injection-site reactions were more frequent but did not lead to discontinuation. Long-term safety data are limited.
Was the drug compared against what payers expect? — Comparator Selection
The trial used placebo as a comparator, which is relevant for establishing efficacy but insufficient for assessing incremental benefit over existing C5 inhibitors like ravulizumab and zilucoplan.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was broadly representative of the target population, but there were limited numbers of Black participants and those with severe disease. Subgroup analyses were not adequately powered or reported.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Gefurulimab can be self-administered weekly, which aligns well with existing care pathways and offers convenience over daily or infusion-based therapies. However, it requires training and monitoring for meningococcal infection.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource-use data were presented, preventing assessment of resource implications.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The phase 3 trial was well-designed with robust statistical controls and high completion rates. However, the lack of an active comparator and reliance on congress abstracts for some data limit the external validity.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While sensitivity analyses for missing data were conducted, significant uncertainties remain regarding long-term efficacy, safety, and economic outcomes. No economic sensitivity analysis was available.
